English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

We report our experience with vincristine, carmustine (BCNU), cyclophosphamide, and prednisone (VBCP), a regimen given in the outpatient setting to patients with multiple myeloma (MM) resistant to almost all the available novel/targeted therapies. Ten patients received salvage VBCP who were heavily pretreated with a median of 5.5 prior treatment regimens including lenalidomide, pomalidomide, bortezomib, carfilzomib, cyclophosphamide, and autologous stem cell transplantation. The objective response rate (≥PR) was 60%, with an additional 30% achieving stable disease (SD). The median time to progression for patients with ≥SD was 3.6 months. The median progression free survival was 4.4 months while the median overall survival was 12.8 months. Despite severe myelosuppression being the main toxicity, 61% of the subsequent cycles were given on time. Treatment-related mortality was not observed. Our results suggest VBCP is a highly active and tolerable salvage regimen among heavily pretreated MM patients who already failed many of the novel agents.

journal of cancer research and therapy

New salvage vincristine, carmustine, cyclophosphamide, and prednisone (VBCP) chemotherapy for relapsed/refractory multiple myeloma in the modern era: A case series